Aisling Capital related stories
All articles and analysis
F2G raises $60 mlnF2G Ltd said June 20 that it raised $60 million in financing led by Sectoral Asset Management. Novo A/S, Aisling Capital and Brace Pharma Capital also invested. Existing investors Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital each participated in the round. F2G is a UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infection.
Fund performance: IVP tops recent vintage New York State portfolioUnexpectedly, late-stage investor IVP leads New York pension fund's venture portfolio that favors small early-stage funds
Fund performance: Asia Alternatives, Aisling, Insight lead late-decade venture portfolioSeveral funds already are posting good, early returns in a Calpers portfolio that is heavy with multi-stage, late-decade funds
- Zavante raises $45 mln to develop injectable antibiotic
Zavante Therapeutics Inc announced that it closed a $45 million Series A round, which the San Diego company will use to develop an injectable antibiotic to treat multidrug resistant (MDR) pathogens. The round was comprised of $35 million from new investors and $10 million from the conversion of outstanding convertible notes. It was co-led by Frazier Healthcare Partners and Longitude Capital, with participation from Aisling Capital. As part of the deal, Frazier Healthcare Managing General Partner Patrick Heron and Longitude Capital Managing Director David Hirsch will join Zavante’s board of directors.
- KKR leads $45 mln round for Spirox
Spirox Inc. said Tuesday it closed a $45 million Series C round led by KKR. Also participating in the round were HealthQuest Capital along with existing investors Aisling Capital, Aperture Venture Partners and Venrock. Menlo Park, California-based Spirox is a medical device company.
- Syros Pharma raises $40 mln
Syros Pharmaceuticals said Tuesday it closed a $40 million financing led by new investor Deerfield Management Company. Also participating were new investor Casdin Capital, as well as existing investors Fidelity Management and Research Company, WuXi Healthcare Ventures, Polaris Partners, Redmile Group, Aisling Capital and Alexandria Venture Investments. Cambridge, Massachusetts-based Syros is a biopharmaceutical company.
- Aguiar joins Aisling Capital
Eric Aguiar, MD, has joined Aisling Capital as a Partner. Dr. Aguiar was previously a Partner at Thomas, McNerney & Partners and before that he was a Managing Director of HealthCare Ventures.
On the move, 8.31.2015The following hires, promotions and appointments are for the August 31, 2015, issue of Buyouts.
Data spotlight: Virtustream deal lifts M&A total in JulySale of enterprise cloud company Virtustream lifted aggregate deal total in the month to nearly $1.5 billion